Mannkind

More in depth research....

1. MannKind Corp. (MNKD, Earnings, Analysts, Financials): Focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Market cap at $528.43M, most recent closing price at $2.15. Over the last six months, insiders were net buyers of 31,269,350 shares, which represents about 24.74% of the company’s 126.38M share float.

http://wire.kapitall.com/investment-idea/6-stocks-under-5-being-bought-up-by-company-insiders/